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Background: To evaluate the clinical effectiveness of a topical sialogogue spray (malic acid, 1%) in the treatment 
of xerostomia in patients with chronic Graft versus Host Disease (cGVHD). 
Material and Methods: This study was designed as a randomized double-blind clinical study. Twenty-eight pa-
tients with cGVHD suffering from xerostomia were divided into 2 groups: the first group (14 patients) received a 
topical sialagogue spray containing malic acid 1% (SalivAktive®) whereas the second group (14 patients) received 
a placebo. Both groups received treatment for 2 weeks. Dry Mouth Questionnaire (DMQ) scores and unstimulated 
salivary flows rate were collected before and after treatment. 
Results: DMQ scores increased significantly from 1.3 ± 0.4 to 3.5 ± 0.4 points (p<0.05) after two weeks of treat-
ment with malic acid, whereas in the control group DMQ scores increased from 1.2 ± 0.7 points to 1.4 ± 0.6 
(p>0.05). The unstimulated salivary flow rate in patients treated with malic acid increased significantly from 0.15 
± 0.06 mL/min to 0.24± 0.08 mL/min, while that of the patients treated with placebo went from 0.16 ± 0.07 mL/
min to 0.17 ± 0.09 mL/min (p>0.05).
Conclusions: Malic acid 1% spray can be considered effective in the treatment of GVHD induced xerostomia.
 




Graft versus host disease (GVHD) is one of the most fre-
quent and serious complications of hematopoietic stem 
cell transplantation. After transplantation, the donor’s T 
lymphocytes may recognize the antigens expressed by 
the re¬cipient’s cells as foreign, inducing an immune re-
action accompanied by intense inflammatory responses. 
The acute presentation of GVHD typically affects the 
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skin, the gastrointestinal tract, and the liver. The chronic 
form is characterized by the involvement of several or-
gans, including the oral cavity, which could represent the 
primary site of chronic GVHD (cGVHD) (1-3).
The prevalence of oral cGVHD ranges between 45-
83%; moreover, the oral cavity could be the only affect-
ed body region (4-5). The specific or distinctive clinical 
oral features comprise oral lichenoid lesions, hyper-
keratotic plaques, mucosal atrophy, erythema, ulcers, 
pseudomembranes, limited oral aperture secondary to 
sclerosis and, last but not least, xerostomia.
Xerostomia can manifest itself with some frequency as 
a consequence of progressive salivary gland damage. 
Salivary gland dysfunction in cGVHD patients mimics 
Sjögren syndrome; it is characterized by histopathologi-
cal changes, consisting of mononuclear infiltration with 
periductal infiltration, and/or atrophy of salivary gland 
lobules and peri-glandular fibrosis (6). Recent studies 
reported that saliva in patients with cGVHD have sig-
nificantly higher concentrations of sodium, magnesium, 
epidermal growth factor, total protein, albumin and im-
munogoblin G (7). As a result of the histopathological 
changes and of the altered salivary concentrations, the 
functional capacities of saliva (i.e. chemical digestion; 
lubrification and cleaning; pH buffering effect; anti-
inflammatory, anti-bacterial and anti-viral activity) are 
impaired. The repercussions are a disruption of the mu-
cosal integrity, insufficient protection against mechani-
cal and chemical epithelial injuries, and reduced anti-
cariogenic activity (7). Furthermore, a dry mouth can 
compromise swallowing, speaking, and sleeping; this, 
in turn, is associated to a worsening of a patient’s qual-
ity of life referred to the oral cavity and due to a dimin-
ished body mass index (8).
Although no standard treatment guidelines are avail-
able, many treatment options exist for the management 
of xerostomia and hypo-salivation, from topical agents 
to systemic therapies. Intraoral topical agents, being free 
of side effects, are among the most commonly recom-
mended treatments for the management of xeros¬tomia. 
The purpose of this study was to evaluate the effective-
ness of a topical sialogogue spray containing malic acid 




Thirty-one consecutive patients were enrolled. Inclu-
sion criteria were transplanted subjects who developed 
cGVHD and dryness in the mouth. Exclusion criteria 
were head-neck radiation therapy, Sjogren’s syndrome 
and/or related autoimmune diseases (rheumatoid ar-
thritis, polyarthritis nodosa, systemic sclerosis or lupus 
erythematosus), diabetes, current xerostomic medica-
tion (anti-hypertensives, anti-depressants, anxiolytics, 
anti-psychotics, anti-cholinergics, adrenergic blockers, 
anti-asthmatics), smoking and chronic alcohol abuse. 
-Study design
This study was designed as a randomized controlled 
clinical study. Sample size was based on the standard 
deviation of the main variable: Dry Mouth Question-
naire (DMQ). A pilot sample of 10 patients was tested 
to determine the minimum sample size necessary to re-
liably confirm the hypothesis that a topical 1% malic 
acid sialogogue spray is effective in treating xerostomia 
induced by cGVHD over a 2 weeks period.
The patients were randomly assigned to two groups. 
Randomization was performed using an automatically 
generated list in a 1:1 block size for two patients. The 
patients included received a number and were randomly 
assigned to one of the two sprays by a member of the 
team who performed a permuted-block randomization 
of the participants. Patients codes where inserted into 
closed envelopes.
The patients were randomized by a computer code into 
two groups: group A, who received a topical sialogogue 
spray (malic acid, 1%) and group B, who received a pla-
cebo (i.e. saline solution). 
The two products shared the same packaging. The 
sprays were applied four times a day. Both patients and 
researchers were blinded throughout the study. 
Dry mouth questionnaire (DMQ)
The DMQ was used to assess the severity of dry mouth 
before and after treatment with malic acid/placebo. (9-
11) Every patient answered the DMQ before receiving 
a spray (1% malic acid or placebo) and after 2 weeks 
of use. Increased DMQ scores indicate improvement of 
dry mouth. The DMQ used a 0-to-4 rating scale where 
0= very dry and 4=not dry at all (Table 1).
-Sialometries
The unstimulated salivary flow rate was obtained by the 
spit method every 30s for 15 minutes. Saliva was col-
lected in 20-mL plastic containers. Measurements were 
expressed as millilitre per minute (13).
-Statistical Analysis
The main purpose was to contrast different DMQ scores 
at T0 and T1 by using the Mann-Whitney U- test. A 5% 
significance level was used for the analysis. Student’s t-
test was used to analyse unstimulated salivary flow rate 
-Ethical Considerations
The research was performed in compliance with the 
Declaration of Helsinki and Good Clinical Practice. All 
patients were informed about the research and signed an 
IRB approved informed consent. Ethical approval for 
the research was granted by the local Ethic Committee.
Results
-Characteristics of the patients
Among the 31 patients with cGVHD complaining of 
xerostomia, 28 met the inclusion criteria (Fig. 1). They 
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Dry Mouth Questionnaire (DMQ) 
  Question Response (scale 0–4) 
How dry is your mouth?  
Are you suffering from oral dryness during daytime?  
Are you suffering from oral dryness at night?  
Do you have a nasty taste in your mouth?  
Is sleeping impeded?  
Is swallowing impeded?  
Is eating impeded?  
 








Table 1. Dry Mouth Questionnaire (DMQ).
Fig. 1. Enrollment flow chart.
were randomly assigned to two groups: group A (n=14, 
malic acid 1%) and group B (n=14, placebo). Table 2 
shows intervention group versus control group results 
in relation to age, gender, DMQ scores and unstimu-
lated salivary flow rate. 
There were no statistically significant differences 
(p>0.05) between the demographic characteristics of 
the two groups; therefore, the two groups were homo-
geneous. 
Variables Intervention group Control group





T0 1.3 ± 0.4 1.2 ± 0.7
T1 3.5 ± 0.4* 1.4 ± 0.6
Unstimulated salivary flow rate
T0 0.15 ± 0.06 mL/min 0.16 ± 0.07 mL/min
T1 0.24± 0.08 mL/min* 0.17 ± 0.09 mL/min
-DMQ scores
DMQ scores increased significantly from 1.3 ± 0.4 to 
3.5 ± 0.4 points (p<0.05) after the two weeks treat-
ment with malic acid, whereas in the control group 
DMQ scores increased from 1.2 ± 0.7 points to 1.4 ± 
0.6 (p>0.05). 
-Unstimulated salivary flow rate
After two weeks of treatment, the unstimulated salivary 
flow rate increased significantly from 0.15 ± 0.06 mL/
min to 0.24± 0.08 mL/min whereas that of the patients 
treated with placebo went from 0.16 ± 0.07 mL/min to 
0.17 ± 0.09 mL/min (p>0.05).
Discussion
Xerostomia, i.e. the subjective sensation of a dry mouth, 
can be either caused by a hypofunction of the salivary 
glands (reduced volume of saliva secretion) or by a 
change in salivary composition. Dry mouth is usually 
associated with difficulty in swallowing, speaking and 
numerous other oral health problems. Since 1989 (14), 
the salivary glands have been recognized as a very 
sensitive target for cGVHD. Reduction in whole saliva 
flow rate in GVHD patients has been reported in many 
studies, as well as various salivary biochemical and im-
munologic compositional alterations. The mechanism 
of salivary involvement depends on the lymphocyte in-
Table 2. Demographic characteristics of the two groups, DMQ scores and unstimulated salivary flow rate.
*Statistically significant difference (p < 0.05) (T0 vs T1).
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filtration, mostly T cells with a predominance of CD8+ 
over CD4+, in the glandular parenchyma, especially 
around the secretor ducts. 
Such periductal infiltration associated with a cytokine 
dysregulation (especially IL-2, IL-6, IFNgamma, TNF 
alfa) are considered responsible for the salivary paren-
chymal atrophy and hypofunction (7,15).
This study was carried out on patients with cGVHD 
complaining of xerostomia. Xerostomia is defined as 
the subjective complaint of dry mouth. Objective pre-
sentation of salivary gland hypofunction does not nec-
essarily reflect a subjective perception of xerostomia 
and vice versa. Interestingly, patients complaining of 
xerostomia frequently do not show any objective sign of 
hypo-salivation and their symptoms may be secondary 
to qualitative and/or quantita¬tive changes in the com-
position of saliva. The content and production of saliva 
by different salivary glands display circadian variations 
affecting different aspects of symptoms related to sali-
vary dysfunction (16,17).
Xerostomia in patients with objective hypo-salivation is 
diagnosed when the rate of saliva flow is less than the 
rate of fluid absorption across the oral mucosa plus the 
rate of fluid evaporation from the mouth (17,18).
The normal unstimulated salivary flow rate is approxi-
mately 0.3–0.4 mL/min (17,19-20).
A diagnosis of hypo-salivation is made when the un-
stimulated salivary flow rate is around 0.1 mL/min 
(17,20-21). Our patients had a baseline salivary flow rate 
ranging from 0.09 to 0.26 mL/min, thus patients with 
a subjective sensation of xerostomia and those with a 
hypo-salivation were included. 
Although no standard treatment guidelines are avail-
able, many treatment options exist for the management 
of xerostomia in cGVHD. Several treatment strategies 
have been recommended in the past years and they all 
aim to reduce patients’ symptoms and/or increase sali-
vary flow. Pilocarpine and cevimeline are two systemic 
US Food and Drug Administration-approved sialo-
gogues. They are effective, but they have many side ef-
fects i.e. excessive sweating, cutaneous vasodilatation, 
emesis, nausea, diarrhea, persistent hiccup, broncho-
constriction, hypotension, bradycardia, increased uri-
nary frequency, and vision problems (17,22). 
Easy remedies are proper hydration, increase in hu-
midity at night-time, avoidance of irritating dentifrices 
and crunchy/hard foods and use of sugar-free chewing 
gums/candy. 
Currently, intraoral topical agents are among the most 
commonly recommended treatments for the manage-
ment of xerostomia. These include saliva stimulants and 
substitutes (23).
Saliva substitutes aim to increase viscosity and mimic 
natural saliva without altering the salivary flow. They 
contain minerals (eg, fluoride, calcium, and phosphate 
ions), carboxymethylcellulose or hydroxyethylcellulose, 
flavoring agents, and preservatives (eg, propyl or methyl 
paraben). Other remedies include mucoadhesive lipid-
based bioerodible tablets or mucin sprays, although 
their efficacy for management of xerostomia remains 
controversial (17,23).
This study aimed to evaluate the effectiveness of a 
topical sialogogue spray containing malic acid 1% in 
patients (Salivaktive®) in patients with cGVHD expe-
riencing xerostomia. The application of topical sialo-
gogues containing acids in the treatment of xerostomia 
isn’t new. However, continuous application of substanc-
es such as citric acid has been related to an increased 
risk of caries, due to the erosive action of these agents 
on dentin (24,25).  
All these products were dropped because of their de-
mineralising effect on human dentin, effect not only 
caused by the high doses of acidic products, but also 
by how the product consumption (chewable products), 
as some allow for a lengthy contact with the dental sur-
faces. Products in a spray format allow for a fast and di-
rect contact with the oral mucosa, and this, if combined 
with a suitable concentration (as the stimulant effect on 
saliva production is not altered by it), could reduce the 
demineralising potential of these substances.
Malic acid acts as a sour tasting gustatory stimulus. Its 
mechanism of action is linked to dissociation of H+ in 
malic acid in water, which becomes hydronium ions 
(H3O+); this action generates a stimulation of salivary 
secretion to dilute the concentration of acids in the oral 
cavity. Xylitol do not stimulate saliva but it reduces ero-
sion and cariogenic potential. Thus, a spray containing 
malic acid with xylitol seems to be a safe topical sialo-
gogue (26,27).
DMQ was used as it is an easy and fast method to as-
sess the efficacy of topical sialogogues. In addition to 
this, its 0-to-4 scale can be easily replaced by a Visual 
Analogue Scale (VAS) of 10 cm. According to DMQ 
scores, feelings of oral dryness among intervention 
group improved significantly in comparison with the 
control group. The results also showed an increase of 
the unstimulated salivary flow rate, after the use of 1% 
malic acid spray for 2 weeks. According to the results 
of our study, the use of malic acid as a salivary stimu-
lant can be a valid option for the treatment of cGVHD-
induced xerostomia. 
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